GlassScriptPhysician profile
Alejandro Mejia
NPI 1508832536
$19,890.61
in general payments reported to CMS, 2019-2025
19 companies · $174 in 2025
The $174 reported for 2025 was less than what a typical Transplant Surgery provider received nationally (typical 2025 total: $423).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,596 · 2020: $4,110 · 2021: $3,284 · 2022: $3,151 · 2023: $226 · 2024: $350 · 2025: $174.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $750.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $749.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $15,628.53 | 2019-2022 | |
| Medical Device Business Services, INC. | $3,030.00 | 2022 | |
| Sirtex Medical INC | $240.89 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $140.35 | 2024 | |
| Histosonics, INC. | $139.66 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $120.74 | 2020-2024 | Xifaxan |
| Medtronic, INC. | $116.77 | 2024 | Signia |
| Gilead Sciences, INC. | $83.14 | 2019-2022 | |
| Abbvie INC. | $80.69 | 2019-2024 | |
| Intercept Pharmaceuticals, INC. | $79.74 | 2023-2024 | Ocaliva |
| Hemosonics LLC | $65.82 | 2023 | Quantra Qplus System |
| Veloxis Pharmaceuticals, INC. | $45.66 | 2019 | |
| Alnylam Pharmaceuticals INC. | $23.45 | 2023 | Oxlumo |
| Tetraphase Pharmaceuticals, INC. | $17.67 | 2019 | |
| Novo Nordisk INC | $17.28 | 2025 | Wegovy |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eton Pharmaceuticals, INC. | $16.82 | 2025 | Betaine Anhydrous, Nitisinone, Carglumic Acid |
| Advanced Accelerator Applications | $16.37 | 2019 | |
| Vivus LLC | $13.57 | 2021 | |
| Ethicon US, LLC | $13.46 | 2023 | Neuwave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alejandro Mejia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.